Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3912353 | 0.97 | KCNA3 (0.55) | KCNA3PTGS2CA12CA1CA9 | |
| SCHEMBL3918098 | 0.92 | KCNA3 (0.57) | KCNA3PTGS2CA12CA1CA9 | |
| SCHEMBL3918141 | 0.89 | KCNA3 (0.60) | KCNA3PTGS2CA12CA1CA9 | |
| Trifluoroacetic Acid SCHEMBL3911993 | 0.84 | KCNA3 (0.60) | KCNA3PTGS2CA12CA1CA9 | |
| Trifluoroacetic Acid SCHEMBL3912558 | 0.84 | HTR2C (0.39) | KCNA3MAOBHPGDSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL3911178 | 0.84 | KCNA3 (0.59) | KCNA3PTGS2CA12CA1CA9 | |
| SCHEMBL3921262 | 0.79 | LMNA (0.62) | KCNA3PTGS2CA12CA1CA9 | |
| SCHEMBL3913362 | 0.75 | KCNA3 (0.42) | KCNA3MAOBHPGDTSHRSMN1; SMN2 | |
| SCHEMBL3909724 | 0.74 | KCNA3 (0.64) | KCNA3PTGS2CA12CA1CA9 | |
| SCHEMBL21533758 | 0.74 | KDM4E (0.45) | KCNA3HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538233-B2 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1667988-A1 | COUMARINS AS INOS INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005026143-A1 | COUMARINS AS INOS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054681-A1 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054681-A1 | Coumarins as iNOS inhibitors | NOS2, NOS1, NOS3 | KCNA3 3807/4885PTGS2 22/4885CA12 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.